 |
 |
|
 |
 |
 |
IQuum Awarded SBIR-NIH Grant for Development of Liat Technology for Point-of-Care Genotyping Allston, MA, July 1, 2004 -- IQuum, Inc. announced today that the company has been awarded a $154,086 phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop a high-level multiplex real time assay for detecting single nucleotide polymorphisms (SNP) at the point-of-care using IQuum's innovative Lab-in-a-tube (Liat™) technology. This research project leverages the unique capabilities of the Liat technology and novel multiplexing strategy to fulfill the need for a rapid, fully-automated, easy-to-use, closed tube sample testing device that can score a moderate number of single nucleotide polymorphisms with minimal cost. Once developed, the Liat system for point-of-care genotyping will facilitate the use of "just-in-time" genotyping in the practice of medicine to evaluate the risks associated with new prescription drugs, in decisions regarding urgent medical procedures, and in other critical applications. About IQuum, Inc. IQuum is a leader in developing lab-in-a-tube technology, a novel biological sample testing platform intended to provide revolutionary benefits to a broad cross section of the bioassay market. The Company's proprietary technology will enable the less experienced professional to perform more sophisticated biological sample testing in a less expensive setting with greater speed. The lab-in-a-tube platform is the foundation of next generation tools for clinical diagnostics, biodefense, and industrial testing. Founded in 1998, IQuum is located in the Boston metropolitan area in Massachusetts. For more information, please visit www.IQuum.com.
|